Company Performance: UCB's financial health, including revenue, profit margins, and debt levels, directly impacts investor confidence and stock price.

Industry Trends: Developments in the biopharmaceutical sector, such as new drug approvals, regulatory changes, and competitor activity, influence UCB's valuation.

Economic Conditions: Macroeconomic factors like interest rates, inflation, and overall economic growth can affect investment sentiment and the availability of capital for biotech companies.

Investor Sentiment: Market perception of UCB's future prospects, driven by news, analyst ratings, and general market optimism or pessimism, plays a significant role.

Clinical Trial Results: Positive or negative outcomes from UCB's clinical trials for new or existing drugs have a substantial impact on stock price.

Regulatory Approvals: Approval of UCB's drugs by regulatory bodies like the FDA and EMA is a major catalyst for stock price increases.

Mergers and Acquisitions: Potential or actual M&A activity involving UCB or its competitors can create volatility and affect the stock's value.

Dividend Policy: UCB's dividend payments or changes to its dividend policy can influence investor demand for the stock.

Global Events: Geopolitical events, such as political instability or global health crises, can introduce uncertainty and impact stock prices across industries.